Characteristics and protective efficacy of human antibodies against M. tuberculosis

人类结核分枝杆菌抗体的特点和保护功效

基本信息

项目摘要

Abstract Active tuberculosis (TB), a transmissible respiratory infection caused by uncontrolled Mycobacterium tuberculosis (Mtb) infection, is worldwide one of the top 10 causes of death. To control this major global public health problem alternative therapies and a more effective vaccine are urgently needed. The currently available Bacillus Calmette-Guerin (BCG) vaccine has been in use for almost a century but provides insufficient protection against TB. A major obstacle in the TB vaccine field is the limited understanding of the full breadth of the immune components involved in the protection against TB. Currently, TB vaccine development is focused on eliciting or boosting cell-mediated immunity, but increasing evidence suggests that antibodies also have a role in the protection against TB. To gain a better understanding of the epitopes involved in human protection and inducible by vaccination, detailed characterization and functional studies of human polyclonal and monoclonal Abs (mAbs) to potentially protective epitopes are required. Antibodies to capsular and other surface polysaccharides are protective against several microbial pathogens, including those with intracellular location. Using novel glycan arrays our published and preliminary data show that human Abs to Mtb surface glycans are highly heterogeneous in their binding specificity and differ in both their reactivity to oligosaccharide motifs and their functions between BCG vaccination and/or controlled (latent) versus uncontrolled (TB) Mtb infection. Our overarching hypotheses are: 1) Human Abs to AM are protective against Mtb, and 2) protection by these Abs arises from reactivity to specific OS motifs within AM. Our specific aims are: 1. To generate and characterize human polyclonal and mAbs to Mtb surface glycans; 2. To determine the effects of Mtb surface- specific human Abs on macrophage functions; and 3. To establish the protective efficacy of Mtb surface- specific human Abs in vivo. Our overarching goal is to identify key immunogenic Mtb glycotopes that render Ab-mediated protection in humans. The information gained could fill a critical gap in the current knowledge of TB immunity and inform new strategies for developing both vaccines and Ab-based immunotherapies against TB.
摘要 活动性结核病(TB),一种由不受控制的分枝杆菌引起的可传播的呼吸道感染 结核病(Mtb)感染是全球十大死亡原因之一。为了控制这个主要的全球公众 健康问题迫切需要替代疗法和更有效疫苗。当前可用的 卡介苗(BCG)疫苗已经使用了几乎世纪,但提供的免疫应答不足。 预防TB。结核病疫苗领域的一个主要障碍是对结核病的全面认识有限。 免疫成分参与预防结核病。目前,结核病疫苗开发的重点是 在引发或增强细胞介导的免疫力,但越来越多的证据表明,抗体也有 在预防结核病方面的作用。为了更好地了解参与人类保护的表位, 和可诱导的疫苗接种,详细的表征和功能研究的人多克隆和 需要针对潜在保护性表位的单克隆抗体(mAb)。抗荚膜抗体和其他抗体 表面多糖对几种微生物病原体具有保护作用,包括那些具有细胞内 位置.使用新的聚糖阵列,我们发表的和初步的数据表明,人抗结核分枝杆菌表面 聚糖在其结合特异性方面是高度异质的,并且在其对寡糖的反应性方面是不同的。 BCG疫苗接种和/或控制(潜伏)与不控制(TB)Mtb之间的基序及其功能 感染我们的首要假设是:1)人抗AM抗体对Mtb具有保护作用,2)保护 通过这些Ab产生对AM内特定OS基序的反应性。我们的具体目标是:1.以生成和 表征针对Mtb表面聚糖的人多克隆抗体和mAb; 2.为了确定结核分枝杆菌表面的影响- 特异性人Ab对巨噬细胞功能的影响;和3.为了确定结核分枝杆菌表面的保护功效- 体内特异性人Ab。我们的首要目标是鉴定关键的免疫原性Mtb糖表位, Ab介导的人体保护作用。所获得的信息可以填补目前对以下问题的认识中的一个关键空白: 结核病免疫力,并为开发疫苗和基于Ab的免疫疗法提供新的战略 TB.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacqueline Michele Achkar其他文献

Jacqueline Michele Achkar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacqueline Michele Achkar', 18)}}的其他基金

Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10439644
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10525039
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10721412
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10119218
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10212240
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Characteristics and protective efficacy of human antibodies against M. tuberculosis
人类结核分枝杆菌抗体的特点和保护功效
  • 批准号:
    10649613
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Host biomarkers for M. tuberculosis infection activity in HIV-infected persons
HIV 感染者中结核分枝杆菌感染活动的宿主生物标志物
  • 批准号:
    9855497
  • 财政年份:
    2016
  • 资助金额:
    $ 78.88万
  • 项目类别:
Host biomarkers for M. tuberculosis infection activity in HIV-infected persons
HIV 感染者中结核分枝杆菌感染活动的宿主生物标志物
  • 批准号:
    9115881
  • 财政年份:
    2016
  • 资助金额:
    $ 78.88万
  • 项目类别:
Novel serological biomarker for rapid tuberculosis diagnosis
用于快速诊断结核病的新型血清学生物标志物
  • 批准号:
    9132479
  • 财政年份:
    2013
  • 资助金额:
    $ 78.88万
  • 项目类别:
Novel serological biomarker for rapid tuberculosis diagnosis
用于快速诊断结核病的新型血清学生物标志物
  • 批准号:
    8721846
  • 财政年份:
    2013
  • 资助金额:
    $ 78.88万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了